Market research
4592.TSE SanBio Company Limited
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 80B
- P/E ratio
- Not available
- Analyst target
- 1480
- Dividend yield
- Not available
- Beta
- 0.29
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3336750009
- Market cap
- 80B
- P/E ratio
- Not available
- Analyst target
- 1480
- Dividend yield
- Not available
- Beta
- 0.29
About
About SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4592.TSE discussion.
5 years, 6 months ago
SanBio Company Limited is currently in a long term downtrend where the price is trading 21.9% below its 200 day moving average.
From a valuation standpoint, the stock is 5930.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 4252.6.
SanBio Company Limited's total revenue sank by 0.0% to $23M since the same quarter in the previous year.
Its net income has increased by 12.9% to $-2B since the same quarter in the previous year.
Based on the above factors, SanBio Company Limited gets an overall score of 1/5.